Translational Development Acquisition Corp.
NASDAQ:TDACShell Companies
-$0.01 today
- Market cap
- $267.99M
- Beta
- 0.01
- P/E (TTM)
- 29.8
- EPS (TTM)
- $0.36
Volume 0.47M
Average 0.10M
TDAC Common Stock Issued
Cash raised by issuing new shares.
Translational Development Acquisition Corp.NASDAQ: TDAC
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued outflow grows to $0
Q1 FY2026 common stock issued was $0, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $0.
Context
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly common stock issued holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 169.05M | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (125.61K) | — |
Common Stock Issued vs competitors
How TDAC compares with its peers on the latest reported figures
- TDAC's LTM Mar 2026 common stock issued of $0 is the 3rd largest of the 7 companies compared; the peer median is $0.
- Its year-over-year change of -100.0% is the highest of 4, against a peer median of -100.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2022 | $282.5M | — | — | — | |
| FY2025 | $231.71M | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
MACIMelar Acquisition Corp. I | LTM Mar 2026 | $0 | -100.0% | — | — |
NTWONewbury Street II Acquisition Corp | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding TDAC) | $0 | -100.0% | — | — | |
Competitors are the stored peer set for TDAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (71) | (485.55K) | (71.01K) | 6.36M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | (75) | 3.01K | (659.81K) | 336.15K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | (449.75K) | 29.01K |
| Other Working Capital | (75) | 3.01K | (210.06K) | 307.14K |
| Other Non-Cash Items | (97.02K) | 482.34K | (120.63K) | (7.31M) |
| Operating Cash Flow | (145) | (204) | (851.45K) | (608.39K) |
| Capital Expenditures | 4 | 0 | (4) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (174.23M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | (174.23M) | 0 |
| Debt Repayment | 225K | 0 | (393.46K) | 200K |
| Common Stock Issued | (125.61K) | 0 | 169.05M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | (125.35K) | 0 |
| Other Financing Activities | 0 | 0 | 6.98M | 0 |
| Financing Cash Flow | 99.39K | 0 | 175.51M | 200K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.23K | (204) | 436.15K | (408.39K) |
| Free Cash Flow | (145) | (204) | (851.45K) | (608.39K) |
Translational Development Acquisition Corp.
NASDAQ:TDAC
Intrinsic Alpha fair value
Locked
Current Price
$10.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.